View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 8, 2021updated 22 Jul 2021 1:16pm

Exscientia receives $1.5m Gates Foundation grant for AI-designed Covid-19 drugs

The project aims to identify drugs that are effective against Covid-19, as well as new mutations or other SARS viruses that could emerge.

By Darcy Jimenez

UK-based artificial intelligence (AI) drug discovery company Exscientia has received a $1.5m grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners to accelerate the development of a new class of Covid-19 drugs.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The grant, awarded as part of the Covid-19 Therapeutics Accelerator initiative, will allow Exscientia to use its AI drug design platform to optimise novel small molecule inhibitors for a therapeutic development candidate.

The goal of the project is to identify potential treatments that are active against SARS-CoV-2 and other coronaviruses, as well as new mutations or other SARS viruses that could emerge.

Exscientia has demonstrated proof-of-concept by using its AI platform to design a new class of inhibitors targeting the SARS-CoV-2’s main protease enzyme, Mpro, also known as 3CLpro, the causative agent of Covid-19.

Mpro is essential for the replication of coronavirus, therefore an Mpro inhibitor, administered to patients as a standalone antiviral or alongside other treatments, could serve as a valuable frontline therapy.

Exscientia ’s senior portfolio manager Dr Denise Barrault commented: “The danger of new emerging strains and mutations of coronavirus means there is an urgent need for new antiviral drugs in this pandemic alongside vaccines, to respond more quickly in potential future coronavirus pandemics.

“We believe that the world needs innovation to accelerate the discovery of more effective counter-measures for a range of infectious diseases, including Covid-19.”

This is not the first time Exscientia has been the recipient of Gates Foundation funding; in December, the company was handed a two-year $4.2m grant to apply its AI-based Centaur platforms to solutions for malaria, tuberculosis and non-hormonal contraception.

The company’s work to tackle these global health challenges began in January.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology